No Data
No Data
Durect Corp Annual Meeting Decisions and Shareholder Votes
Durect Agreement on Larsucosterol Trial 'a Major Positive,' Says Northland
Durect Analyst Ratings
Express News | DURECT Corp - Phase 3 Trial to Enroll 200 U.S. Patients
Express News | DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-Associated Hepatitis
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
No Data
No Data